Clinical Trial: Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia
Brief Summary:
RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer.
PURPOSE: Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer.
Detailed Summary:
OBJECTIVES:
- Determine the frequency of cytopenic response in patients with T-cell large granular lymphocytic leukemia treated with cyclosporine.
OUTLINE: This is a multicenter study.
Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 4 months for 1 year and then every 6 months for 9 years.
PROJECTED ACCRUAL: A total of 9-30 patients will be accrued for this study within 3 years.
Sponsor: Alliance for Clinical Trials in Oncology
Current Primary Outcome: Frequency of cytopemic response [ Time Frame: Up to 10 years ]
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Alliance for Clinical Trials in Oncology
Dates:
Date Received: March 8, 2002
Date Started: March 2002
Date Completion:
Last Updated: July 1, 2016
Last Verified: July 2016
